Literature DB >> 6413286

The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.

I D Young, P S Harper.   

Abstract

During a national survey of Hunter's syndrome, 52 boys with the severe form were ascertained. The average ages of onset and death were 2.47 and 11.77 years respectively. Most patients had a large head and short stature. Persistent diarrhoea was noted in 65 per cent of the patients. 76 per cent had an umbilical hernia. Right and left inguinal herniae were noted in 51 and 32 per cent respectively. Evidence of cardiovascular disease was found in 65 per cent of cases; and serious lower respiratory-tract disease occurred in 84 per cent. Induction of anaesthesia proved difficult or impossible in five boys. The disease pattern was dominated by the effects of neurological involvement, with initial developmental delay and behavioural disturbance, followed by regression, with convulsions and pyramidal tract signs. Death was due primarily to this neurodegenerative cachexia, with superimposed respiratory disease.

Entities:  

Mesh:

Year:  1983        PMID: 6413286     DOI: 10.1111/j.1469-8749.1983.tb13794.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  40 in total

1.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

2.  Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease).

Authors:  J de Ruijter; L Broere; M F Mulder; A T van der Ploeg; M E Rubio-Gozalbo; S B Wortmann; G Visser; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

3.  Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunter.

Authors:  M Westhoff; P Litterst
Journal:  JIMD Rep       Date:  2011-12-16

4.  Activity of daily living for Morquio A syndrome.

Authors:  Eriko Yasuda; Yasuyuki Suzuki; Tsutomu Shimada; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Li Xie; Freeman Miller; Tariq Rahman; Heidi H Kecskemethy; Kyoko Nagao; Thierry Morlet; Thomas H Shaffer; Yasutsugu Chinen; Hiromasa Yabe; Akemi Tanaka; Haruo Shintaku; Kenji E Orii; Koji O Orii; Robert W Mason; Adriana M Montaño; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-04-25       Impact factor: 4.797

5.  Long-term follow-up following bone marrow transplantation for Hunter disease.

Authors:  A Vellodi; E Young; A Cooper; V Lidchi; B Winchester; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

6.  Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

Authors:  Annerose Keilmann; Todsaporn Nakarat; Iain A Bruce; David Molter; Gunilla Malm
Journal:  J Inherit Metab Dis       Date:  2011-08-25       Impact factor: 4.982

7.  Sanfilippo syndrome.

Authors:  K S Devi; P Veerraju; B S Rao
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

8.  The Hunter syndrome-functional outcomes for clinical understanding scale (HS-FOCUS) questionnaire: evaluation of measurement properties.

Authors:  Ingela Wiklund; Mireia Raluy-Callado; Donald E Stull; Yvonne Jangelind; David A H Whiteman; Wen-Hung Chen
Journal:  Qual Life Res       Date:  2012-05-19       Impact factor: 4.147

Review 9.  Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

Authors:  E M Cross; D J Hare
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

10.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.